Pritor

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
10-12-2020
Opinber matsskýrsla Opinber matsskýrsla (PAR)
05-11-2015

Virkt innihaldsefni:

Telmisartan

Fáanlegur frá:

Bayer AG

ATC númer:

C09CA07

INN (Alþjóðlegt nafn):

telmisartan

Meðferðarhópur:

Agents acting on the renin-angiotensin system

Lækningarsvæði:

Hypertension

Ábendingar:

HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage.

Vörulýsing:

Revision: 29

Leyfisstaða:

Authorised

Leyfisdagur:

1998-12-11

Upplýsingar fylgiseðill

                                35
B. PACKAGE LEAFLET
36
PACKAGE LEAFLET: INFORMATION FOR THE USER
PRITOR 20 MG TABLETS
telmisartan
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pritor is and what it is used for
2.
What you need to know before you take Pritor
3.
How to take Pritor
4.
Possible side effects
5.
How to store Pritor
6.
Contents of the pack and other information
1.
WHAT PRITOR IS AND WHAT IT IS USED FOR
Pritor belongs to a class of medicines known as angiotensin II
receptor antagonists. Angiotensin II is a
substance produced in your body which causes your blood vessels to
narrow, thus increasing your
blood pressure. Pritor blocks the effect of angiotensin II so that the
blood vessels relax, and your
blood pressure is lowered.
PRITOR IS USED TO treat essential hypertension (high blood pressure)
in adults. ‘Essential’ means that
the high blood pressure is not caused by any other condition.
High blood pressure, if not treated, can damage blood vessels in
several organs, which could lead
sometimes to heart attack, heart or kidney failure, stroke, or
blindness. There are usually no symptoms
of high blood pressure before damage occurs. Thus it is important to
regularly measure blood pressure
to verify if it is within the normal range.
PRITOR IS ALSO USED TO reduce cardiovascular events (i.e. heart attack
or stroke) in adults who are at
risk because they have a reduced or blocked blood supply to the heart
or legs, or have had a stroke or
have high risk diabetes. Your doctor can tell you if you are at high
risk for suc
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Pritor 20 mg tablets
Pritor 40 mg tablets
Pritor 80 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pritor 20 mg tablets
Each tablet contains 20 mg telmisartan.
Pritor 40 mg tablets
Each tablet contains 40 mg telmisartan.
Pritor 80 mg tablets
Each tablet contains 80 mg telmisartan.
Excipients with known effect
Each 20 mg tablet contains 84 mg sorbitol (E420).
Each 40 mg tablet contains 169 mg sorbitol (E420).
Each 80 mg tablet contains 338 mg sorbitol (E420).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pritor 20 mg tablets
White round tablets of 2.5 mm engraved with the code number '50H' on
one side and the company
logo on the other side.
Pritor 40 mg tablets
White oblong tablets of 3.8 mm engraved with the code number '51H' on
one side.
Pritor 80 mg tablets
White oblong tablets of 4.6 mm engraved with the code number '52H' on
one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Hypertension
Treatment of essential hypertension in adults.
Cardiovascular prevention
Reduction of cardiovascular morbidity in adults with:

manifest atherothrombotic cardiovascular disease (history of coronary
heart disease, stroke, or
peripheral arterial disease) or

type 2 diabetes mellitus with documented target organ damage
3
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Treatment of essential hypertension_
The usually effective dose is 40 mg once daily. Some patients may
already benefit at a daily dose of
20 mg. In cases where the target blood pressure is not achieved, the
dose of telmisartan can be
increased to a maximum of 80 mg once daily. Alternatively, telmisartan
may be used in combination
with thiazide-type diuretics such as hydrochlorothiazide, which has
been shown to have an additive
blood pressure lowering effect with telmisartan. When considering
raising the dose, it must be borne
in mind that the maximum antihypertensive effect is generally attained
four to eight weeks after the

                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 10-12-2020
Vara einkenni Vara einkenni búlgarska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla búlgarska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 10-12-2020
Vara einkenni Vara einkenni spænska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla spænska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 10-12-2020
Vara einkenni Vara einkenni tékkneska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla tékkneska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 10-12-2020
Vara einkenni Vara einkenni danska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla danska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 10-12-2020
Vara einkenni Vara einkenni þýska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla þýska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 10-12-2020
Vara einkenni Vara einkenni eistneska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla eistneska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 10-12-2020
Vara einkenni Vara einkenni gríska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla gríska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 10-12-2020
Vara einkenni Vara einkenni franska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla franska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 10-12-2020
Vara einkenni Vara einkenni ítalska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla ítalska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 10-12-2020
Vara einkenni Vara einkenni lettneska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla lettneska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 10-12-2020
Vara einkenni Vara einkenni litháíska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla litháíska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 10-12-2020
Vara einkenni Vara einkenni ungverska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla ungverska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 10-12-2020
Vara einkenni Vara einkenni maltneska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla maltneska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 10-12-2020
Vara einkenni Vara einkenni hollenska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla hollenska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 10-12-2020
Vara einkenni Vara einkenni pólska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla pólska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 10-12-2020
Vara einkenni Vara einkenni portúgalska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla portúgalska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 10-12-2020
Vara einkenni Vara einkenni rúmenska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla rúmenska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 10-12-2020
Vara einkenni Vara einkenni slóvakíska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 10-12-2020
Vara einkenni Vara einkenni slóvenska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla slóvenska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 10-12-2020
Vara einkenni Vara einkenni finnska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla finnska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 10-12-2020
Vara einkenni Vara einkenni sænska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla sænska 05-11-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 10-12-2020
Vara einkenni Vara einkenni norska 10-12-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 10-12-2020
Vara einkenni Vara einkenni íslenska 10-12-2020
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 10-12-2020
Vara einkenni Vara einkenni króatíska 10-12-2020
Opinber matsskýrsla Opinber matsskýrsla króatíska 05-11-2015

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu